On February 6th, Lynn Lewis, Founder & CEO of Gilmartin Group, hosted a webinar with J.P. Morgan’s Annie Wernig and Benjamin Burdett. According to insights shared during the event, the MedTech market outlook for 2025 is signaling a significant rebound in investor interest and market activity. After facing headwinds in recent years, the sector appears poised for growth, with renewed momentum from both public and private investors.
KEY TAKEAWAYS:
Strong Fundamentals Drive Optimism in MedTech
MedTech saw a notable improvement in the consistency around preannouncements this year with many echoing key themes such as healthy procedure volume, pricing and strong underlying fundamentals. Procedure volumes are trending upward, pricing remains stable, and inflationary pressures have moderated. While not entirely immune to macro pressures, the sector has demonstrated resilience, supported by strong balance sheets across the industry. Commentary on Q4 and 2025 outlooks have set up the MedTech sector favorably. As a result, sentiment has strengthened, setting the stage for potentially a good year. These trends support a positive MedTech market outlook for 2025, with favorable fundamentals reinforcing investor confidence.
The Return of IPOs
After a three-year drought, the MedTech IPO market has reopened with successful offerings from Ceribell and Beta Bionics. These debuts have established important benchmarks and signal renewed momentum, reinforcing a strong MedTech market outlook 2025. The extended drought has created a significant pent-up backlog of companies eager to go public, and the improvement in valuations are encouraging as we begin to re-establish a base line of transaction comps.
For companies considering an IPO, key success factors include:
- Demonstrated commercial predictability
- Clear path to MedTech-level margins (high 60-70%)
- Convincing roadmap to profitability
- De-risked regulatory and reimbursement profile
- Sufficient capital raised at IPO to reach profitability without additional fundraising
While revenue scale remains important, with typical candidates showing $40-60 million in run-rate revenue, the focus has shifted toward business fundamentals and execution capability rather than strict revenue thresholds.
M&A Activity Heating Up
The M&A market has continued its momentum, with well-capitalized strategic buyers pursuing growth opportunities. Recent deal activity has focused on de-risked assets with commercial scale, though opportunities exist across the maturity spectrum. The improved financing environment and IPO market have helped create competitive tension in processes, potentially benefiting sellers. Strategic deal-making continues to play a critical role in shaping the MedTech market outlook 2025.
Mid-cap companies are increasingly active in M&A, though they face challenges competing with larger strategics for premium assets. Their focus tends toward targeted acquisitions in niche markets or highly synergistic tuck-in opportunities that enhance core capabilities, drive efficiency, and accelerate innovation while maintaining financial discipline. The market is expected to remain active throughout the course of 2025.
Evolving Investor Landscape
Investor interest in MedTech is evolving, with a noticeable shift toward generalist investors who appreciate the sector’s strong fundamentals and relative insulation from policy risks. This broader interest signals confidence in the MedTech market outlook for 2025, particularly given the sector’s resilience. Unlike biotech, crossover rounds are not mandatory for MedTech IPO candidates, but can provide strategic advantages, particularly in helping larger funds build meaningful positions. Current market conditions have sparked increased interest from crossover investors looking to participate in the next wave of MedTech public offerings, further contributing to the sector’s promising outlook.
Capital Markets Strategy: The Best Offense is a Good Defense
In today’s evolving market, management teams must remain proactive to capitalize on emerging opportunities. Engaging with investors is critical to maintain transparency, shaping sentiment, and positioning for future capital raises. Companies should also take strategic steps such as filing shelf-registrations to ensure flexibility in accessing capital when conditions are favorable. This approach helps avoid market speculation about near-term financing needs.
Additionally, proactively de-risking the business – whether through operational efficiencies, balance sheet optimization, or strategic diversification – can enhance resilience and attract long-term investment. By staying ahead of market shifts and maintaining a disciplined approach, companies can position themselves for success in the evolving MedTech market outlook 2025.
Why the MedTech Market Outlook for 2025 Signals a Rebound
As the MedTech sector navigates 2025, companies are encouraged to maintain their focus on core business execution rather than timing markets or engineering specific outcomes. The best results typically come from management teams dedicated to delivering superior products and expanding their market presence, while working with experienced advisors to optimize their capital markets strategy.
For companies considering going public, early preparation is crucial, with ideal timelines suggesting initial dialogue with potential advisors at least a year before any potential IPO. This approach allows for thorough preparation while managing internal resources and maintaining focus on core business operations.
The MedTech sector appears well-positioned for 2025, with multiple pathways to value creation through public markets, M&A, and organic growth. Success will likely favor companies that maintain strong execution while taking advantage of the improved market environment to advance their strategic objectives—and thrive in the MedTech market outlook 2025.
Conclusion:
MedTech is poised for a better year ahead, with incremental data pointing to a constructive and optimistic outlook. Good earnings growth and a positive outlook for 2025 reflect the sector’s resilience and continued innovation. Additionally, the long-awaited reopening of the IPO market provides MedTech companies with fresh opportunities for capital raising and expansion. At the same time, increased M&A activity signal confidence in strategic growth through consolidation and targeted acquisitions. With these tailwinds in place, the MedTech sector is well-positioned for sustained momentum and value creation in the coming year.
The team at Gilmartin Group has extensive experience working with both private and public companies across the Medtech, Biotech, Life Science Tools & Diagnostics, Digital Health & HCIT sectors. To find out more about how we strategically partner with our clients, please do not hesitate to contact our team today.
Authored by: Vivian Cervantes (Managing Director), Greg Chodaczek (Managing Director), and Steve Yeung (Associate Vice President).